<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04040023</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A01522-55</org_study_id>
    <nct_id>NCT04040023</nct_id>
  </id_info>
  <brief_title>Patient Blood Management in Cardiac Surgery</brief_title>
  <acronym>PBMc</acronym>
  <official_title>Optimization of Transfusion Use and Interest of the Correction of Iron Deficiencies in Cardiac Surgery Under Extracorporeal Circulation (ECC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinique Pasteur</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinique Pasteur</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preoperative anemia is associated with an important increase in transfusions of red blood&#xD;
      cells (RBC) compared to a non-anemic patient in cardiac and non cardiac surgery. Furthermore&#xD;
      transfusion is also an independent factor of morbi-mortality with notably an increase in the&#xD;
      infectious risk, immunological, an increase of the risk of cardiac decompensation,&#xD;
      respiratory decompensation Transfusion Related Acute Lung Injury (TRALI) or Transfusion&#xD;
      Associated Cardiac Overload (TACO), and an increase in mortality of 16%.&#xD;
&#xD;
      Management of perioperative transfusion is therefore a public health issue. Since 2010, the&#xD;
      World Health Organization (WHO) has been promoting a systematic approach to implement blood&#xD;
      management programs for the patient to optimize the use of resources and promote quality and&#xD;
      safety of care.&#xD;
&#xD;
      Improving the relevance of transfusion in cardiac surgery could be achieved by optimizing the&#xD;
      management of patients around 2 axis:&#xD;
&#xD;
      A:non-drug intervention : Review of Practices to Improve the Management of Perioperative RBC&#xD;
      Transfusion&#xD;
&#xD;
      B:drug intervention : Systematic correction of pre- and postoperative iron, vitamin&#xD;
      deficiencies and anemia&#xD;
&#xD;
      The aim of this program is to improve the relevance of transfusion in cardiac surgery and to&#xD;
      limit the morbidity and mortality induced by transfusion. This program is part of a global&#xD;
      project of pre, per and postoperative management of the patient undergoing cardiac surgery&#xD;
      programmed under extracorporeal circulation (ECC). It requires a multidisciplinary approach&#xD;
      between cardiologists, anesthesiologists and intensivists, perfusionists, cardiac surgeons&#xD;
      and paramedical teams to optimize the management of the patient.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Actual">September 23, 2021</completion_date>
  <primary_completion_date type="Actual">July 24, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Prospective monocentric superiority study in two successive steps</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RBC transfusion rate</measure>
    <time_frame>Between surgery and hospital discharge, an average of 10 days</time_frame>
    <description>Proportion of patient who received at least one RBC transfusion during their hospitalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>between baseline (1 month before surgery) and 3 months after surgery</time_frame>
    <description>Occurrence of adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion parameters</measure>
    <time_frame>between surgery and hospital discharge, an average of 10 days</time_frame>
    <description>Transfusion rate, use of poly transfusion, hemodilution, transfusion thresholds and postoperative bleeding volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood test parameters</measure>
    <time_frame>between baseline (1 month before surgery) and 3 months after surgery</time_frame>
    <description>hemoglobin, ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 min walk test</measure>
    <time_frame>at discharge of the healthcare and rehabilitation units</time_frame>
    <description>Walking test : distance reach after 6 min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA)</measure>
    <time_frame>between baseline (1 month before surgery) and 3 months after surgery</time_frame>
    <description>NYHA Functional Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro Quality of life 5 dimensions (EQ5D)</measure>
    <time_frame>between baseline (1 month before surgery) and 3 months after surgery</time_frame>
    <description>EQ5D Quality of life questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">900</enrollment>
  <condition>Surgical Blood Loss</condition>
  <arm_group>
    <arm_group_label>I Group: PBMi</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non-drug intervention First part of PBM program (PBMi) Training part for medical care staff to improve transfusion practices</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C Group: PBMc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient Blood Management: full program&#xD;
PBMi intervention and Drug intervention (systematic correction of pre- and postoperative iron and vitamin deficiencies, and erythropoietin preoperative treatment for anemic patient)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron and vitamin Deficiencies Correction Program</intervention_name>
    <description>Preoperative:&#xD;
For patient with iron deficiency: Intravenous iron supplementation For patient with folic acid or vitamin B12 deficiency : oral vitamin supplementation For patient with anemia: pre operative erythropoietin injections&#xD;
Postoperative:&#xD;
Systematic iron supplementation</description>
    <arm_group_label>C Group: PBMc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PBMi: Training program to improve transfusion practices</intervention_name>
    <description>Training program to sensitize health care staff to streamline the use of transfusion targeting the following points: limit perioperative and post operative hemodilution; to adapt the transfusion threshold to the tolerance of the patient to anemia in per and postoperative; justify the use of RBC transfusion by setting up a questionnaire; encourage transfusion of RBC unit by unit.</description>
    <arm_group_label>C Group: PBMc</arm_group_label>
    <arm_group_label>I Group: PBMi</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient scheduled for cardiac surgery under ECC&#xD;
&#xD;
          -  Patient affiliated or beneficiary of a social security scheme&#xD;
&#xD;
          -  Patient having given his consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Urgent surgery (less than 48h)&#xD;
&#xD;
          -  Contraindication to iron injection : proven allergic reaction&#xD;
&#xD;
          -  Erythropoietin allergy&#xD;
&#xD;
          -  Protected patients: Majors under some form of guardianship or other legal protection;&#xD;
             pregnant, breastfeeding or parturient woman.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène Charbonneau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse cedex 3</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinique Pasteur</investigator_affiliation>
    <investigator_full_name>Dr Hélène Charbonneau</investigator_full_name>
    <investigator_title>Principal investigator, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Red Blood Cell transfusion</keyword>
  <keyword>Anemia</keyword>
  <keyword>Iron deficiency</keyword>
  <keyword>Extracorporeal circulation or Bypass</keyword>
  <keyword>Cardiac Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

